The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means that the location of commercialization is often different from where IP is developed. Therefore, understanding the financial implications of transfer pricing caused by differentials in country corporate income tax rates can legally and significantly minimize country tax liabilities.
The econometric analysis outlined here can also help generate greater drug financial returns that can be used to plow back into R&D, the future lifeblood of any biopharmaceutical company, especially given the increasing cost and risk of R&D for specialty medicines. This white paper also demonstrates a different area not traditionally thought of where commercial analytics can be successfully applied for biopharmaceutical companies given changes in the biopharmaceutical external environment.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Fill in your details to get a copy of this whitepaper, and contact us at firstname.lastname@example.org for any questions.